Design
Review
Authors
Loading...
Supports evaluation in ACS trials; leaves open whether primate antithrombotic effects and bleeding profile translate to patients.
PAR-1 antagonists represent a novel class of antithrombotic agents that may offer efficacy in arterial thrombosis with reduced bleeding risk compared to conventional anticoagulants.
Chackalamannil et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: